Glaxo's melanoma drug Mekinist was recommended by the EMA for treatment of the dangerous skin cancer. Mekinist was already approved in the USA last year and is a key asset for Novartis in their acquisition of GSK's oncology product line -- priced at $14.5 B. Mekinist is currently in a clinical trial to test the effectiveness of it in combination with GSK's Taflinar. If the trial is successful, then Novartis will pay GSK another $1.5 B in the deal. See Bloomberg.
Posted by Bruce Lehr April 26th 2014.